This guide outlines essential postmarket cybersecurity strategies for medical device manufacturers to maintain FDA compliance, protect patient safety, and minimize business impact from emerging threats. It emphasizes continuous monitoring, proactive vulnerability management, and robust incident response planning to secure devices throughout their operational lifecycle.
Every CVE deserves a recorded outcome - even "not affected" - to satisfy FDA postmarket expectations.
Utilize automated tools to continuously track your Software Bill of Materials (SBOM) for all devices. This helps detect vulnerabilities in third-party and open-source components as soon as they are identified, enabling proactive responses.
Set up systems to actively monitor cyber threats across your device ecosystem and receive instant notifications for CVEs affecting your devices. This allows for rapid mitigation before threats impact device functionality or patient safety.
Create and regularly update proven incident response playbooks tailored for medical device patient-safety scenarios. These plans should minimize downtime, ensure audit-ready documentation, and protect both patients and your brand during a cybersecurity incident.
Implement tailored risk mitigation strategies for older devices that may not be patchable. Focus on compensating controls to extend their lifecycle while balancing safety, functionality, and compliance.
Generate audit-ready reports and exportable evidence that align with FDA postmarket guidance for all cybersecurity activities. This simplifies compliance and streamlines the audit process.
Perform annual penetration testing and static application security testing (SAST) on your full device and ecosystem. This proactively identifies vulnerabilities and weaknesses before they can be exploited.
Implement a process to assess each identified cybersecurity vulnerability within its clinical context, integrating ISO 14971 risk management principles. Prioritize remediation steps based on potential patient safety impact.
Utilize a secure dashboard to track vulnerabilities, patches, and incidents in real-time. This provides full visibility and simplifies the management of your postmarket security posture.
A published CVD policy without an operating Product Security Incident Response Team is a common deficiency. Document your PSIRT cadence: intake triage SLA, severity rubric, coordination with CISA/ICS-CERT, and disclosure timeline. Keep a redacted example on file.
When marking a CVE 'not_affected' in a VEX statement, use one of the five standard justifications: component_not_present, vulnerable_code_not_present, vulnerable_code_not_in_execute_path, vulnerable_code_cannot_be_controlled_by_adversary, or inline_mitigations_already_exist. Free-text 'not applicable' is being flagged as unsupported.
Wire the CISA Known Exploited Vulnerabilities (KEV) catalog into your SBOM-monitoring pipeline. A KEV hit on any component in your device is a priority-one triage event regardless of CVSS score.
Every release should produce an SBOM diff against the prior version. Reviewers increasingly ask what changed component-wise between submissions — a diffing workflow (syft + grype, or equivalent) makes this trivial and demonstrates operational maturity.
Authoritative guidance and standards underpinning this topic. Always confirm the latest revision with the publisher.
Quick answers to the questions teams most often ask about this topic.
Manufacturers must monitor for new vulnerabilities affecting their devices (including third-party components in the SBOM), triage them against patient safety impact, remediate on defined timelines, and coordinate disclosure. Section 524B and the FDA's 2016 postmarket guidance define the framework.
CVD is the published process by which security researchers can report vulnerabilities to you, receive acknowledgment, and coordinate on public disclosure once a fix is available. Every 'cyber device' manufacturer is expected to have and publish a CVD policy.
There is no bright-line statutory number. FDA expects timing to be justified by patient-safety risk, using an established framework such as CVSS or the ISPE Patch Framework. In practice, 30-90 days is typical for high-risk issues; anything longer needs explicit compensating controls.
Notify customers when the vulnerability represents uncontrolled risk, when compensating controls are needed while a patch is developed, or when the fix requires customer action. Silent patching is not acceptable for issues that materially affect device security posture.
Yes. FDA expects manufacturers to reserve and publish CVEs for vulnerabilities affecting their devices and to coordinate with CISA's ICS-MEDICAL advisory program where applicable. CVE issuance is essential for downstream hospital vulnerability tracking.
Start here. The big picture for MedTech security.
What's in scope (hardware, firmware, wireless, cloud, mobile), the methods reviewers expect, and how to read a pentest report against FDA cybersecurity guidance.
Continuous vulnerability monitoring for fielded devices.